Evidence-based Psychopharmacology
Erschienen am 21. Juli 2005
Buch
Softcover
380 Seiten
978-0-521-53188-7 (ISBN)
Beschreibung
This book presents a comprehensive overview of recent advances in evidence-based pharmacological treatment of psychiatric disorders. There have been very significant developments in our understanding of the methods for systematically reviewing literature, assessing clinical trials and optimising decision making. The book explores these issues and applies the lessons learned to the practical management of major psychiatric conditions, addressing issues such as selecting the best first-line psychopharmacological intervention for a particular disorder, how long a particular intervention should be continued, and identifying the next-best treatment strategy should the first agent fail. Conditions covered include, amongst others, depression, schizophrenia, panic, PTSD, OCD, ADHD and eating disorders. The potential for complications as a result of adverse interactions between drugs is also examined. These issues lie at the heart of clinical psychopharmacology and the book will therefore appeal to all practising clinicians, whether in a primary care or a specialist mental health setting.
Rezensionen / Stimmen
'... will certainly be widely consulted, and hopefully followed, by psychiatrists and clinical psychopharmacologists.' Human PsychopharmacologyWeitere Details
Sprache
Englisch
Verlagsort
Cambridge
Großbritannien
Zielgruppe
Für Beruf und Forschung
Produkt-Hinweis
Broschur/Paperback
Maße
Höhe: 248 mm
Breite: 176 mm
Dicke: 23 mm
Gewicht
735 gr
ISBN-13
978-0-521-53188-7 (9780521531887)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Weitere Ausgaben
Nachauflagen
Dan Stein | Bernard Lerer | Stephen M. Stahl
Essential Evidence-Based Psychopharmacology
Buch
07/2012
2. Auflage
Cambridge University Press
107,60 €
Versand in 15-20 Tagen
Personen
Inhalt
1. Evidence-based pharmacotherapy of major depressive disorder Michael Ostacher, Jeffrey Huffman, Roy Perlis and Andrew A. Nierenberg; 2. Evidence-based pharmacotherapy of bipolar disorder S. Nassir Ghaemi and Douglas J. Hsu; 3. Evidence-based pharmacotherapy of schizophrenia Robin Emsley and Piet Oosthuizen; 4. Evidence-based pharmacotherapy of generalised anxiety disorder David S. Baldwin and Claire Polkinghorn; 5. Evidence-based pharmacotherapy of panic disorder Abraham Bakker, Anton J. L. M. van Balkom and Dan J. Stein; 6. Evidence-based pharmacotherapy of post-traumatic stress disorder C. Barbara Portier, Abraham Bakker, Anton J. L. M. van Balkom and Dan J. Stein; 7. Evidence-based pharmacotherapy of social anxiety disorder Carlos Blanco, Muhammad S. Raza, Franklin R. Schneier and Michael R. Liebowitz; 8. Evidence-based pharmacotherapy of obsessive-compulsive disorder Naomi A. Fineberg and Tim M. Gale; 9. Evidence-based pharmacotherapy of eating disorders Martine F. Flament, Claudia Furino and Nathalie Godart; 10. Evidence-based pharmacotherapy of attention deficit hyperactivity disorder Joseph Biederman, Thomas Spencer and Timothy Wilens; 11. Evidence-based pharmacotherapy of Alzheimer's Disease John G. Evans, Gordon Wilcock and Jacqueline Birks; 12. Drug interactions C. Lindsay DeVane.